Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes

Obesity Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01926938
• Other study ID #: CHS#: 03-30
• Status: Completed
• Phase: N/A
• First received: August 19, 2013
• Last updated: August 20, 2013
• Start date: May 2003
• Est. completion date: January 2013

Study information

• Verified date: August 2013
• Source: Joslin Diabetes Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Diabetes is a major public health problem. Hispanics/Latinos are known to be at higher risk for type 2 diabetes. The function of the endothelium has played a key role in the understanding of vascular complications in people with diabetes. Endothelial function and vascular reactivity are impaired not only in white adults with type 2 diabetes but also in those at risk for the disease by virtue of having impaired glucose tolerance or parental history of type 2 diabetes. Whether this finding is applicable to hispanics is not known. The investigators plan to assess the endothelial function and vascular reactivity in young Hispanic adults at risk of developing type 2 diabetes by virtue of being obese and belonging to a minority population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Group 1:

1. Age between 18-40 years;

2. Hispanic (we will consider a subject being Hispanic if both parents are reported as Hispanics when asked the following question: "What ethnic group do you consider that you belong to?");

3. History of type 2 diabetes in one or both parents;

4. BMI above 27;

5. Not have participated in any exercise program for the 6 months prior to the beginning of the study.

Group 2:

1. Age between 18-40 years;

2. Hispanic (same criteria as above );

3. No history of type 2 diabetes in any first degree relative;

4. BMI under 25;

5. Not have participated in any exercise program for the 6 months prior to the beginning of the study.

Exclusion Criteria:

• diabetes, glucose intolerance, pregnancy, smoking, cardiovascular disease, uncontrolled hypertension, renal disease, proteinuria, cancer, infectious diseases, severe GI diseases, lung disease, electrolyte abnormalities, anemia, endocrine disorders, severe dyslipidemia, peripheral vascular disease, medications: beta-blockers, any diuretic, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, niacin, glucocorticoids, any antineoplastic agent, antibiotics, psychoactive agents, bronchodilators or insulin.

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Insulin Resistance
• Obesity

Locations

Country	Name	City	State
United States	Joslin Diabetes Center	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Joslin Diabetes Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	markers of endothelial activation, coagulation and inflammation		cross sectional evaluation	No